HOOKIPA Pharma Investor Relations Material

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer and chronic infectious diseases. The company utilizes a proprietary arenavirus platform, pioneering technologies that engineer arenaviruses to elicit robust and durable antigen-specific T cell responses and pathogen-neutralizing antibodies. HOOKIPA's innovative approach aims to reprogram the immune system to more effectively combat diseases, with its diverse pipeline addressing significant unmet medical needs in various therapeutic areas. The company is headquartered in New York, and its shares are listed on the NASDAQ.